Premorbid functioning and treatment response in recent-onset schizophrenia

Jonathan Rabinowitz, Philip D Harvey, Marielle Eerdekens, Michael Davidson

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Background: Investigating the relationship between premorbid functioning and treatment response in schizophrenia is relevant to understanding the illness and predicting treatment outcomes. Aims: To examine the relationship between premorbid characteristics and treatment response of people with recent-onset schizophrenia. Method: Data came from a large, double-blind trial of recent-onset psychosis treated with a flexible dose of risperidone or haloperidol. Median treatment length was 206 days. Premorbid functioning was categorised using the Cannon-Spoor Premorbid Adjustment Scale. Results: There were significant differences between the premorbid groups on change on the Positive and Negative Syndrome Scale, Clinical Global Impression severity and cognitive functioning and Extrapyramidal Symptoms Rating Scale. Patients in the 'stable-good' premorbid group (n=251) improved more than those in the 'stable-poor' (n=198) and 'declining' (n=81) groups. The 'stable-good' group received the lowest doses of antipsychotic and had the least extrapyramidal symptoms. Patients in the 'declining' group had the highest dosages and the most extrapyramidal symptoms. Conclusions: In first-episode psychosis good premorbid functioning is associated with better response to treatment and fewer extrapyramidal symptoms. Declaration of interest: None.

Original languageEnglish
Pages (from-to)31-35
Number of pages5
JournalBritish Journal of Psychiatry
Volume189
Issue numberJULY
DOIs
StatePublished - Jul 1 2006
Externally publishedYes

Fingerprint

Schizophrenia
Psychotic Disorders
Social Adjustment
Risperidone
Haloperidol
Therapeutics
Antipsychotic Agents

ASJC Scopus subject areas

  • Neuroscience(all)
  • Psychiatry and Mental health

Cite this

Premorbid functioning and treatment response in recent-onset schizophrenia. / Rabinowitz, Jonathan; Harvey, Philip D; Eerdekens, Marielle; Davidson, Michael.

In: British Journal of Psychiatry, Vol. 189, No. JULY, 01.07.2006, p. 31-35.

Research output: Contribution to journalArticle

Rabinowitz, Jonathan ; Harvey, Philip D ; Eerdekens, Marielle ; Davidson, Michael. / Premorbid functioning and treatment response in recent-onset schizophrenia. In: British Journal of Psychiatry. 2006 ; Vol. 189, No. JULY. pp. 31-35.
@article{a45e184ecefb4af29387f40f1594a366,
title = "Premorbid functioning and treatment response in recent-onset schizophrenia",
abstract = "Background: Investigating the relationship between premorbid functioning and treatment response in schizophrenia is relevant to understanding the illness and predicting treatment outcomes. Aims: To examine the relationship between premorbid characteristics and treatment response of people with recent-onset schizophrenia. Method: Data came from a large, double-blind trial of recent-onset psychosis treated with a flexible dose of risperidone or haloperidol. Median treatment length was 206 days. Premorbid functioning was categorised using the Cannon-Spoor Premorbid Adjustment Scale. Results: There were significant differences between the premorbid groups on change on the Positive and Negative Syndrome Scale, Clinical Global Impression severity and cognitive functioning and Extrapyramidal Symptoms Rating Scale. Patients in the 'stable-good' premorbid group (n=251) improved more than those in the 'stable-poor' (n=198) and 'declining' (n=81) groups. The 'stable-good' group received the lowest doses of antipsychotic and had the least extrapyramidal symptoms. Patients in the 'declining' group had the highest dosages and the most extrapyramidal symptoms. Conclusions: In first-episode psychosis good premorbid functioning is associated with better response to treatment and fewer extrapyramidal symptoms. Declaration of interest: None.",
author = "Jonathan Rabinowitz and Harvey, {Philip D} and Marielle Eerdekens and Michael Davidson",
year = "2006",
month = "7",
day = "1",
doi = "10.1192/bjp.bp.105.013276",
language = "English",
volume = "189",
pages = "31--35",
journal = "British Journal of Psychiatry",
issn = "0007-1250",
publisher = "Royal College of Psychiatrists",
number = "JULY",

}

TY - JOUR

T1 - Premorbid functioning and treatment response in recent-onset schizophrenia

AU - Rabinowitz, Jonathan

AU - Harvey, Philip D

AU - Eerdekens, Marielle

AU - Davidson, Michael

PY - 2006/7/1

Y1 - 2006/7/1

N2 - Background: Investigating the relationship between premorbid functioning and treatment response in schizophrenia is relevant to understanding the illness and predicting treatment outcomes. Aims: To examine the relationship between premorbid characteristics and treatment response of people with recent-onset schizophrenia. Method: Data came from a large, double-blind trial of recent-onset psychosis treated with a flexible dose of risperidone or haloperidol. Median treatment length was 206 days. Premorbid functioning was categorised using the Cannon-Spoor Premorbid Adjustment Scale. Results: There were significant differences between the premorbid groups on change on the Positive and Negative Syndrome Scale, Clinical Global Impression severity and cognitive functioning and Extrapyramidal Symptoms Rating Scale. Patients in the 'stable-good' premorbid group (n=251) improved more than those in the 'stable-poor' (n=198) and 'declining' (n=81) groups. The 'stable-good' group received the lowest doses of antipsychotic and had the least extrapyramidal symptoms. Patients in the 'declining' group had the highest dosages and the most extrapyramidal symptoms. Conclusions: In first-episode psychosis good premorbid functioning is associated with better response to treatment and fewer extrapyramidal symptoms. Declaration of interest: None.

AB - Background: Investigating the relationship between premorbid functioning and treatment response in schizophrenia is relevant to understanding the illness and predicting treatment outcomes. Aims: To examine the relationship between premorbid characteristics and treatment response of people with recent-onset schizophrenia. Method: Data came from a large, double-blind trial of recent-onset psychosis treated with a flexible dose of risperidone or haloperidol. Median treatment length was 206 days. Premorbid functioning was categorised using the Cannon-Spoor Premorbid Adjustment Scale. Results: There were significant differences between the premorbid groups on change on the Positive and Negative Syndrome Scale, Clinical Global Impression severity and cognitive functioning and Extrapyramidal Symptoms Rating Scale. Patients in the 'stable-good' premorbid group (n=251) improved more than those in the 'stable-poor' (n=198) and 'declining' (n=81) groups. The 'stable-good' group received the lowest doses of antipsychotic and had the least extrapyramidal symptoms. Patients in the 'declining' group had the highest dosages and the most extrapyramidal symptoms. Conclusions: In first-episode psychosis good premorbid functioning is associated with better response to treatment and fewer extrapyramidal symptoms. Declaration of interest: None.

UR - http://www.scopus.com/inward/record.url?scp=33745789169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745789169&partnerID=8YFLogxK

U2 - 10.1192/bjp.bp.105.013276

DO - 10.1192/bjp.bp.105.013276

M3 - Article

C2 - 16816303

AN - SCOPUS:33745789169

VL - 189

SP - 31

EP - 35

JO - British Journal of Psychiatry

JF - British Journal of Psychiatry

SN - 0007-1250

IS - JULY

ER -